Poomani Merlin Sobia, Mariappan Iyyadurai, Perumal Ramachandran, Regurajan Rathika, Muthan Krishnaveni, Subramanian Venkatesh
Department of Biotechnology, Manonmaniam Sundaranar University, Tirunelveli 627012, Tamil Nadu, India.
Trichy Medical Center and Hospital, Tiruchirapalli 620018, Tamil Nadu, India.
Glob Heart. 2022 Mar 3;17(1):19. doi: 10.5334/gh.1098. eCollection 2022.
Although tremendous progress has been made in conventional treatment for ischemic heart disease, it still remains a major cause of death and disability. Cell-based therapeutics holds an exciting frontier of research for complete cardiac recuperation. The capacity of diverse stem and progenitor cells to stimulate cardiac renewal has been analysed, with promising results in both pre-clinical and clinical trials. Mesenchymal stem cells have been ascertained to have regenerative ability via a variety of mechanisms, including differentiation from the mesoderm lineage, immunomodulatory properties, and paracrine effects. Also, their availability, maintenance, and ability to replenish endogenous stem cell niches have rendered them suitable for front-line research. This review schemes to outline the use of mesenchymal stem cell therapeutics for ischemic heart disease, their characteristics, the potent mechanisms of mesenchymal stem cell-based heart regeneration, and highlight preclinical data. Additionally, we discuss the results of the clinical trials to date as well as ongoing clinical trials on ischemic heart disease.
尽管在缺血性心脏病的传统治疗方面已经取得了巨大进展，但它仍然是死亡和残疾的主要原因。基于细胞的疗法为心脏完全康复带来了令人兴奋的前沿研究。已经分析了多种干细胞和祖细胞刺激心脏更新的能力，在临床前和临床试验中都取得了有希望的结果。间充质干细胞已被确定通过多种机制具有再生能力，包括从中胚层谱系分化、免疫调节特性和旁分泌作用。此外，它们的可获得性、维持能力以及补充内源性干细胞龛的能力使其适合一线研究。本综述旨在概述间充质干细胞疗法在缺血性心脏病中的应用、它们的特性、基于间充质干细胞的心脏再生的潜在机制，并突出临床前数据。此外，我们还讨论了迄今为止的临床试验结果以及正在进行的缺血性心脏病临床试验。
